Related Experiment Video

Updated: May 13, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology?

Toshio Miyata1, Norio Suzuki, Charles van Ypersele de Strihou

  • 1United Centers for Advanced Research and Translational Medicine (ART), Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Kidney International
|March 15, 2013
PubMed

Insights

Novel therapies targeting oxygen biology, including hypoxia and oxidative stress (OS), show promise for diabetic nephropathy (DN). Exploring cellular mechanisms of oxygen anomalies may lead to new treatments for DN and related diseases.

Area of Science:

  • Nephrology
  • Cellular Biology
  • Biochemistry

Background:

  • Standard treatments for diabetic nephropathy (DN) targeting blood pressure, glucose, insulin, and lipids are insufficient.
  • Oxygen biology anomalies, including hypoxia, oxidative stress (OS), and dyserythropoiesis, are increasingly implicated in DN pathogenesis.
  • Understanding the cellular mechanisms of these oxygen-related anomalies is crucial for developing new therapeutic strategies.

Purpose of the Study:

  • To review the cellular mechanisms of hypoxia, oxidative stress, and dyserythropoiesis in diabetic nephropathy (DN).
  • To identify novel therapeutic targets within oxygen biology pathways for DN treatment.
  • To explore the potential of targeting oxygen homeostasis for broader disease applications.

Main Methods:

  • Review of existing literature on oxygen biology and its role in diabetic nephropathy (DN).
  • Analysis of cellular pathways including the PHD-HIF system for hypoxia and the Keap1-Nrf2 system for oxidative stress.
  • Examination of the role of erythropoietin (EPO) and renal EPO-producing (REP) cells in renal fibrosis.

Main Results:

  • The PHD-HIF and Keap1-Nrf2 systems are key regulators of cellular responses to hypoxia and oxidative stress (OS), respectively.
  • Clinical trials are investigating PHD inhibitors for anemia in chronic kidney disease (CKD) and Nrf2 activators for DN.
  • Renal EPO-producing (REP) cells, not fibroblasts, contribute to renal fibrosis through transdifferentiation.

Conclusions:

  • Targeting oxygen biology pathways offers a promising avenue for novel diabetic nephropathy (DN) therapies.
  • Specific inhibitors of PHD1 and Keap1, along with hemoglobin allosteric effectors, represent potential novel treatments.
  • Restoring REP cell function may offer a strategy to retard renal fibrosis, with broader implications for diseases involving hypoxia and OS.

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.